Moderna Says Its COVID-19 Vaccine Is, Safe and Effective, in 12- to 17-Year-Olds.
On Tuesday, Moderna announced the results of their Phase 2 trial of the administration of their COVID-19 vaccine to children ages 12 to 17.
According to results involving 3,732 children in the United States, their vaccine produces an immune response to COVID-19.
That immune response was found to be equivalent to the immune response produced in adults.
Moderna’s results in the children were “consistent with a vaccine efficacy of 100%.”.
The vaccine was found to be 93 percent effective at preventing mild cases of COVID-19 after one dose.
These mild cases only involved one symptom of COVID-19, rather than two or more.
No significant safety concerns were identified: only mild side effects after the second dose such as headache, fatigue, muscle pain, pain at the injection site and chills.
Moderna plans to submit their findings and a request for authorization to the U.S. Food and Drug Administration in early June.
Currently, Pfizer’s COVID-19 vaccine is the only one to have gained emergency use authorization from the FDA to include 12- to 15-year-olds